Latest Stories
UFP Industries (NASDAQ:UFPI) Misses Q4 CY2025 Revenue Estimates
Building materials manufacturer UFP Industries (NASDAQ:UFPI) fell short of the market’s revenue expectations in Q4 CY2025, with sales falling 9% year on year to $1.33 billion. Its GAAP profit of $0.70 per share was 34% below analysts’ consensus estimates.
John Bean (NYSE:JBTM) Exceeds Q4 CY2025 Expectations
Food processing and aviation equipment manufacturer John Bean (NYSE:JBT) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 116% year on year to $1.01 billion. The company’s full-year revenue guidance of $4.03 billion at the midpoint came in 2.3% above analysts’ estimates. Its non-GAAP profit of $1.98 per share was 2.7% above analysts’ consensus estimates.
BWX (NYSE:BWXT) Delivers Impressive Q4 CY2025, Stock Soars
Aerospace and defense company BWX (NYSE:BWXT) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 18.7% year on year to $885.8 million. Its non-GAAP profit of $1.08 per share was 22.2% above analysts’ consensus estimates.
Kratos (NASDAQ:KTOS) Delivers Impressive Q4 CY2025
Aerospace and defense company Kratos (NASDAQ:KTOS) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 21.9% year on year to $345.1 million. Revenue guidance for the full year exceeded analysts’ estimates, but next quarter’s guidance of $340 million was less impressive, coming in 0.7% below expectations. Its non-GAAP profit of $0.18 per share was 22.1% above analysts’ consensus estimates.
Primoris (NYSE:PRIM) Surprises With Strong Q4 CY2025 But Stock Drops
Infrastructure construction company Primoris (NYSE:PRIM) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 6.7% year on year to $1.86 billion. Its non-GAAP profit of $1.08 per share was 8.9% above analysts’ consensus estimates.
Boise Cascade (NYSE:BCC) Exceeds Q4 CY2025 Expectations
Building products company Boise Cascade Company (NYSE:BCC) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, but sales fell by 6.8% year on year to $1.46 billion. Its GAAP profit of $0.24 per share was significantly above analysts’ consensus estimates.
Erie Indemnity (NASDAQ:ERIE) Misses Q4 CY2025 Revenue Estimates
Insurance management company Erie Indemnity (NASDAQ:ERIE) fell short of the market’s revenue expectations in Q4 CY2025 as sales rose 2.9% year on year to $951 million. Its GAAP profit of $1.21 per share was 23.9% below analysts’ consensus estimates.
Addus HomeCare (NASDAQ:ADUS) Reports Q4 CY2025 In Line With Expectations
Home healthcare provider Addus HomeCare (NASDAQ:ADUS) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 25.6% year on year to $373.1 million. Its non-GAAP profit of $1.77 per share was 2.6% above analysts’ consensus estimates.
Hims & Hers Health’s (NYSE:HIMS) Q4 CY2025 Earnings Results: Revenue In Line With Expectations
Telehealth company Hims & Hers Health (NYSE:HIMS) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 28.4% year on year to $617.8 million. On the other hand, next quarter’s revenue guidance of $612.5 million was less impressive, coming in 5.6% below analysts’ estimates. Its GAAP profit of $0.08 per share was 92.5% above analysts’ consensus estimates.
Myriad Genetics’s (NASDAQ:MYGN) Q4 CY2025 Sales Top Estimates, Stock Jumps 22%
Genetic testing company Myriad Genetics (NASDAQ:MYGN) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, but sales were flat year on year at $209.8 million. The company expects the full year’s revenue to be around $870 million, close to analysts’ estimates. Its non-GAAP profit of $0.04 per share was significantly above analysts’ consensus estimates.